This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Calendar: Key Dates for October

BOSTON ( TheStreet) -- The October biotech calendar is chock-full of potentially stock moving events, including a dozen drugs facing U.S. approval decisions.

Phase III or pivotal studies that could report results in October:

  • Bristol-Myers (BMY) Squibb's melanoma drug ipilimumab.
  • Corcept Therapeutics' (CORT) Corlux in Cushing's syndrome.
  • Seattle Genetics' (SGEN) brentuximab vedotin in anaplastic large cell lymphoma.
  • Cyclacel Pharmaceuticals' (CYCC) seliciclib in non-small cell lung cancer.

Oct. 1

FDA drug approval decision: Hospira' (HSP) Dyloject for acute moderate-to-severe pain in adults.

FDA drug approval decisions: Johnson & Johnson (JNJ) Nucynta for pain indications.

Oct. 4

FDA drug approval decision: Human Genome Sciences' (HGSI) Zalbin for hepatitis C.

Oct. 8-12

European Society for Medical Oncology annual meeting. Data presentations to include Johnson & Johnson (JNJ) (abiraterone), Oxigene (OXGN) (Zybrestat), Seattle Genetics (SGN-75), Allos Therapeutics (ALTH) (Folotyn) and Arqule (ARQL) (ARQ197).

The Obesity Society annual meeting. Stocks of interest include Arena Pharmaceuticals (ARNA), Vivus (VVUS - Get Report) and Orexigen Therapeutics (OREX).

Oct. 11

FDA drug approval decision: Alexza Pharmaceuticals' (ALXA - Get Report) AZ-004 for agitation in patients with schizophrenia or bipolar disorder.

FDA drug approval decision: Jazz Pharmaceuticals' (JAZZ) JZP-6 for fibromyalgia.

Oct. 12

FDA drug approval decision: Alkermes (ALKS - Get Report) Vivitrol for opioid addiction.

Oct 13-16

European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. Data presentations to include Sanofi-Aventis (SNY) (Teriflunomide), Biogen Idec (BIIB) and Elan (ELN) (Tysabri) and Genzyme (GENZ) (Campath).

Oct. 18

FDA advisory panel to discuss the use of erythropoeisis-stimulating agents in the treatment of patients with chronic kidney failure. Amgen (AMGN) (Aranesp, Epogen), Johnson & Johnson (Procrit) and Affymax (AFFY) (Hematide).

Oct. 19

BioMarin Pharmaceuticals (BMRN) analyst/investor day.

Oct. 20

Genzyme third-quarter earnings announcement.

Oct. 22

FDA drug approval decision: Arena Pharmaceuticals' (ARNA) lorcaserin for obesity

FDA drug approval decision: Amylin Pharmaceuticals (AMLN), Alkermes and Eli Lilly's (LLY) Bydureon for diabetes.

Oct. 28

FDA drug approval decision: Vivus' (VVUS - Get Report) Qnexa for obesity.

Oct. 29

FDA drug approval decision: Avanir Pharmaceuticals' (AVNR) Zenvia for pseudobulbar affect.

FDA drug approval decision: Forest Labs (FRX) ceftaroline for Community Acquired Pneumonia. Oct. 30

FDA drug approval decision: Biodel's (BIOD) Linjeta for diabetes.

Exact Sciences (EXAS - Get Report) presentation of external validation study of its genetic stool test for colon cancer.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AVNR $16.96 0.00%
ALKS $61.35 0.00%
ALXA $1.04 0.00%
BIOD $1.11 0.00%
EXAS $26.20 0.00%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs